Juddson Chason, MD
Urology · Annapolis, MDNPI 1376668228
Payments from drug & device makers
Across 465 payments — averaging $42.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$12K
- Astellas Pharma US Inc$2K
- Johnson & Johnson$1K
- Pfizer$819
- Sumitomo Pharma America, Inc.$548
- AbbVie$447
- plus $3K from 33 others
What the payments were for
- Consulting fees$9,20046%
- Travel & lodging$1,7359%
- Food & beverage$8,00540%
- Education$9255%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 32 | $11,910 |
| Astellas Pharma US Inc | 106 | $2,069 |
| Johnson & Johnson(2 entities) | 62 | $1,198 |
| Pfizer | 51 | $819 |
| Sumitomo Pharma America, Inc. | 50 | $548 |
| AbbVie | 22 | $447 |
| Bayer | 11 | $325 |
| Hollister Incorporated | 17 | $315 |
| Myovant Sciences Inc. | 23 | $313 |
| Tolmar, Inc. | 11 | $250 |
| Merck | 11 | $210 |
| Tolmar Pharmaceuticals, Inc. | 10 | $199 |
| C. R. Bard, Inc. & Subsidiaries | 6 | $119 |
| Axonics, Inc. | 4 | $113 |
| Urovant Sciences Inc | 5 | $105 |
| Blue Earth Diagnostics | 6 | $102 |
| Procept Biorobotics Corporation | 1 | $100 |
| Ferring Pharmaceuticals Inc. | 5 | $88 |
| Amgen | 4 | $79 |
| Kowa Pharmaceuticals America, Inc. | 5 | $79 |
| Dentsply IH Inc. | 2 | $50 |
| Olympus America Inc. | 2 | $41 |
| Endo Pharmaceuticals Inc. | 2 | $41 |
| Palette Life Sciences, Inc. | 1 | $40 |
| Neotract Inc. | 1 | $27 |
| Coloplast | 1 | $27 |
| Laborie Medical Technologies Corp. | 1 | $26 |
| Smith+Nephew | 1 | $22 |
| Dendreon Pharmaceuticals LLC | 1 | $21 |
| Argon Medical Devices, Inc. | 1 | $21 |
| Teleflex LLC | 1 | $21 |
| Urogen Pharma, Inc. | 1 | $20 |
| Immunitybio, Inc. | 1 | $20 |
| AstraZeneca | 1 | $19 |
| Janssen Scientific Affairs, LLC | 1 | $18 |
| Medtronic | 1 | $18 |
| Kerecis Limited | 1 | $17 |
| Intuitive Surgical | 2 | $14 |
| Merz Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMAGER II$4,000
- OPTIFLEX$2,800
- NEPHROMAX$2,400
- GENERAL KIDNEY STONE DISEASE$613
- Nubeqa$125
- HARMONIC Product Family$122
- VISTASEAL Fibrin Sealant (Human)$122
- STRATAFIX$122
- EMS SWISS LITHOCLAST TRIOLOGY$117
- AQUABEAM SYSTEM$100
How this compares
$19,866 in reported general payments places this provider in the 80th percentile of 274 urology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 34 | $769,178 |
| XtandiEnzalutamide | 13 | $183,788 |
| MyrbetriqMirabegron | 119 | $88,835 |
| GemtesaVibegron | 48 | $35,241 |
| Mirabegron ErMirabegron | 50 | $29,468 |
| BotoxOnabotulinumtoxina | 18 | $13,293 |
| Tamsulosin Hcl | 364 | $6,934 |
| Potassium Citrate ErPotassium Citrate | 78 | $5,545 |
| Dutasteride | 86 | $3,909 |
| Gentamicin Sulfate | 28 | $2,897 |
| Finasteride | 160 | $2,892 |
| Trospium Chloride | 16 | $802 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 12 | $482 |
| Bicalutamide | 17 | $449 |
| NitrofurantoinNitrofurantoin Macrocrystal | 11 | $443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $1,198 | $769,17834 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $2,069 | $272,623132 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $548 | $35,24148 claims |
| AbbVieBotox | $447 | $13,29318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 274 urology providers in Maryland.
Other urology in Annapolis
- Richard LevinAnnapolis$453K
- David McDermottAnnapolis$19K
- Shaoqing ZhouAnnapolis$15K
- James MastersonAnnapolis$14K
- Mara HoltonAnnapolis$13K
- Matthew AllawayCumberland$20.6M
- Ronald TutroneBaltimore$18.1M
- Mohamad AllafBaltimore$7.1M
- Max KatesBaltimore$1000K
- Benjamin LowentrittBaltimore$994K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.